New insider activity at Mirum Pharmaceuticals ( (MIRM) ) has taken place on February 5, 2025.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Two high-ranking executives at Mirum Pharmaceuticals have recently sold shares of the company’s stock. Peter Radovich, Senior Vice President of Operations, sold 2,627 shares, amounting to a transaction worth $126,673. Meanwhile, Chief Financial Officer Christopher Peetz sold 9,102 shares, with the sale totaling $438,898. These transactions highlight significant insider trading activity within the company.
Recent Updates on MIRM stock
In the last 24 hours, Mirum Pharmaceuticals has seen positive developments leading to an increase in its stock price target from $69 to $74 by JMP Securities. The price target adjustment is attributed to Mirum exceeding its 2024 sales guidance, alongside significant advances in its commercial business and development milestones. The company has expanded its leadership in cholestatic disease with a label expansion for LIVMARLI, and positive interim analyses for volixibat in PSC and PBC, as well as progress in rare genetic neurology with the NDA submission for chenodiol and in-licensing of MRM-3379 for Fragile X syndrome. Furthermore, Mirum’s guidance for 2025 projects continued revenue growth with global net product sales expected to reach between $420 million and $435 million, coupled with positive cash flow from operations.
More about Mirum Pharmaceuticals
YTD Price Performance: 15.58%
Average Trading Volume: 444,944
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.33B